Original Article

Retrospective Study

Protective effects of female reproductive factors on gastric signet-ring cell carcinoma

Yang Li, Yu-Xin Zhong, Quan Xu, Yan-Tao Tian

Yang Li, Yu-Xin Zhong, Quan Xu, Yan-Tao Tian, Department of Pancreatic and Gastric Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Corresponding author: Yan-Tao Tian, MD, Chief Doctor, Department of Pancreatic and Gastric Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 South Panjiayuan Lane, Suite 806, Surgical Building, Chaoyang District, Beijing 100021, China. tianyantao@cicams.ac.cn

Abstract

BACKGROUND
The overall incidence of gastric cancer is higher in men than women worldwide. However, gastric signet-ring cell carcinoma (GSRC) is more frequently observed in younger female patients.

AIM
To analyze clinicopathological differences between sexes in GSRC, because of the limited evidence regarding association between sex-specific differences and survival.

METHODS
We reviewed medical records for 1431 patients who received treatment for GSRC at the Cancer Hospital, Chinese Academy of Medical Sciences between January 2011 and December 2018 and surveyed reproductive factors. Clinicopathological characteristics were compared between female and male patients. Cox multivariable model was used to compare the mortality risks of GSRC among women, menstrual women, and menopausal women.

RESULTS
Of 1431 patients, 935 patients were male and 496 were female (181 menstrual and 315 menopausal). The 5-year overall survival in male, menstrual female and menopausal female groups was 65.6%, 76.5% and 65%, respectively ($P < 0.01$). Menstruation was found to be a protective factor (hazard ratio = 0.58, 95% confidence interval: 0.42–0.82).

CONCLUSION
The mortality risk of GSRC in menstrual women was lower than that in men. This study identified the protective effects of female reproductive factors in GSRC.

**Key Words:** Gastric carcinoma; Signet-ring cell; Female reproductive factor; Menopause

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** The overall incidence of gastric cancer is higher in men than in women worldwide. However, gastric signet-ring cell carcinoma (GSRC) is more frequently observed in younger female patients. Only a few studies have focused on sex-specific differences in GSRC. This study proposed clinicopathological differences between sexes to reveal sex disparities in GSRC and confirmed that female reproductive factors provided protective effects, and the mortality risk of menstrual female patients was lower. Investigation of the mechanism of action of female reproductive factors may provide new insight into the treatment of GSRC.

**Citation:** Li Y, Zhong YX, Xu Q, Tian YT. Protective effects of female reproductive factors on gastric signet-ring cell carcinoma. *World J Clin Cases* 2022; 10(16): 5217-5229
**URL:** https://www.wjgnet.com/2307-8960/full/v10/i16/5217.htm
**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i16.5217

**INTRODUCTION**

Gastric cancer (GC) is the fifth most common adenocarcinoma and ranks third in mortality worldwide [1]. In China, an estimated 390000 people die of GC annually, which accounts for > 50% of the global deaths and imposes a severe health burden[1-3]. Commonly, the age-standardized incidence rates of GC have shown a male predominance with the male-to-female rate of more than 2:1 in most populations around the world[1,4]. The difference, however, cannot be entirely attributed to the different prevalence of established major risk factors, such as tobacco smoking[5] and *Helicobacter pylori* infection[6] between the sexes. A study reported that incidence of intestinal GC after menopause increased with time, and the incidence 10 years after menopause was comparable to that of men[7]. An umbrella review including 616 630 women in six observational studies showed that menopausal hormonal therapy was associated with decreased risk of GC[8]. The female reproductive factors and sex hormones may have protective effects on gastric adenocarcinoma.

Gastric signet-ring cell carcinoma (GSRC) is a distinct type of GC, and its incidence has been steadily increasing in Asia, Europe, and the United States, accounting for > 30% of new gastric adenocarcinoma cases[9]. GSRC belongs to the diffused, undifferentiated, and poorly differentiated types in the Laurén classification, Nakamura’s classification, and Japanese Gastric Cancer Association, respectively[10-13]. GSRC in early and advanced stages is more frequently observed in younger female patients than gastric adenocarcinoma[14]. A contradiction with the protective effect of female reproductive factors on gastric adenocarcinoma seems to exist. There is also evidence that female reproductive factors induce diffuse-type GC through estrogen activity[7].

Moreover, various reproductive factors have provided contradictory results in relation to the risk of GCs. The protective effects of female reproductive factors imply the potential role of sex hormones in carcinogenesis. Importantly, the explanation for the predominance of GSRC in young women might provide significant clues to the etiology of the tumors and pave the way for research on innovative prevention and treatment. The effect of female reproductive factors on GSRC tumorigenesis and tumor development remains unclear despite the advances in the understanding of its epidemiology and clinicopathology. The purpose of this study was to estimate the effects of female reproductive factors on the prognosis and combined modality treatment of GSRC.

**MATERIALS AND METHODS**

**Study population and follow-up duration**

Our study involved 1431 participants who were histologically confirmed with GC with signet-ring cells and underwent curative resection between January 2011 and December 2018 at the Cancer Hospital, Chinese Academy of Medical Sciences, China. Subtotal gastrectomy was performed for distal GCs, whereas total gastrectomy was conducted for proximal-third GCs. Patients with definitive signs of distant organ or peritoneal seeding metastases did not undergo gastrectomy and were referred for
evaluation for chemotherapy instead. Based on the National Comprehensive Cancer Network Clinical Practice Guidelines, standard D2 lymphadenectomy was achieved in patients with curative intention [15]. All the surgical specimens were confirmed separately and independently by at least two experienced pathologists. Disagreements were resolved by discussion, especially on the proportion of signet-ring cells. The follow-up data were prospectively collected and regularly updated by surgeons every 6 mo after surgery. The overall survival was defined from the date of gastrectomy to the date of death or the end of follow-up period (April 30, 2020).

**Measurements**

The demographic characteristics included age and body mass index (BMI). We considered age as an ordinal variable (< 50, 50–60, and ≥ 60 years) to approximate tertiles. We defined BMI based on the standard cutoff points established by the Work Group on Obesity in China in categories of underweight and normal: ≤ 24 kg/m², overweight and obese: > 24.0 kg/m²[16]. Health-related lifestyle indicators, including alcohol consumption (yes: Any alcoholic beverage consumption in the last 12 mo, or no: No alcohol consumption in the last 12 mo) and smoking (yes: Any regular tobacco consumption, or no: Never smoked), were excluded from the analysis based on the variable selection outcome of best-subset selection approach and the uneven distribution. We categorized the proportion of signet-ring cells as ≤ 10%, 10%–50%, 50%–90%, and > 90%, but we used the proportion of signet-ring cells as a dichotomous variable (≤ 50% and > 50%) in the adjustments for confounding variables and to ensure that each level had a sufficient number of observations. Clinicopathological characteristics, such as BMI, proportion of signet-ring cells, T stage, N stage, adjuvant chemotherapy, neoadjuvant chemotherapy, nerve invasion, and lymphatic vessel invasion were subjected to analysis since they were closely associated with the survival of GC patients with signet-ring cell carcinoma based on *a priori* knowledge.

**Statistical analysis**

The continuous variables were expressed as mean ± SD, while categorical variables were expressed as number of observations and percentages (%). Differences in the potential covariates between the sex groups were assessed by Wilcoxon–Mann–Whitney test for continuous variables and the χ² test for categorical variables. The proportional hazards assumption was estimated, and the Cox multivariable model was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between the sex factors and survival of GC patients with signet-ring cell carcinoma. The model was adjusted for following potential covariates: BMI, proportion of signet-ring cells, T stage, N stage, adjuvant chemotherapy, neoadjuvant chemotherapy, nerve invasion, and lymphatic vessel invasion. Subgroup analyses were conducted by (1) BMI; (2) Signet-ring cells proportion; (3) Adjuvant chemotherapy; (4) Neoadjuvant chemotherapy; (5) Nerve invasion; and (6) Lymphatic vessel invasion to explore if the impact of the sex difference was stronger in certain groups. Interaction terms between exposures and these covariates were added into the multivariable model, and Wald tests were used to examine whether the interaction terms were statistically significant. The survival curves were estimated by the Kaplan–Meier method. In the present analysis, two-sided *P* < 0.05 was considered to indicate statistically significant differences. All statistical analyses (and figures created) were performed with Stata 15.0 (StataCorp LLC: College Station, TX, United States).

**RESULTS**

**Clinicopathological features of GSRC in male and female patients**

Table 1 displays the distributions of the demographic and potential risk factors by sex difference. Of the 1431 GC patients with signet-ring cell carcinoma, 935 (65.3%) were male, and 496 (34.7%) were female. Overall, over one-third of the participants were aged ≥ 60 (42.0%) years, with a mean age of 56.3 (SD: 11.3) years. There were no significant differences between the sex groups in terms of histological differentiation, N stage, and adjuvant or neoadjuvant chemotherapy (*P* > 0.05). The female subjects were more likely to be: younger, nonsmokers and nondrinkers; with diffuse Lauren type, T1 stage and metastasis; without nerve and lymphovascular invasion; and have middle and lower tumor location, lower BMI, higher signet-ring cells proportion, and more lymph nodes removed (*P* < 0.05). The Cox proportional hazards regression model results are presented in Table 2. Overall, the menstrual women had a significantly lower risk of mortality (HR = 0.58, 95%CI: 0.42–0.82) than male patients in the multivariable model. We did not observe this protective effect in menopausal women (HR = 0.91, 95%CI: 0.72–1.14).

**Subgroup analysis in the different sex groups with GSRC**

Other variables associated with the overall survival included BMI, T stage, N stage, adjuvant or neoadjuvant chemotherapy, and lymphovascular invasion. The results of the subgroup analyses (Table 3) showed that the impact of menstruation was more significant in the female participants with lower levels of signet-ring cells (HR = 0.56, 95%CI: 0.38–0.82, *P*-interaction = 0.038), nerve invasion (yes
| Characteristics                  | Overall (n = 1431, %) | Male (n = 935, 65.3%) | Female (n = 496, 34.7%) | P value<sup>1</sup> |
|---------------------------------|----------------------|----------------------|------------------------|---------------------|
| **Age (yr)**                    |                      |                      |                        |                     |
| mean ± SD                       | 56.3 ± 11.3          | 57.5 ± 10.7          | 54.2 ± 12.1            | < 0.01              |
| < 50                            | 386 (27.0)           | 213 (55.2)           | 173 (44.8)             | < 0.01              |
| ≥ 50, < 60                      | 444 (31.0)           | 303 (68.2)           | 141 (31.8)             |                     |
| ≥ 60                            | 601 (42.0)           | 419 (69.7)           | 182 (30.3)             |                     |
| **BMI (kg/m<sup>2</sup>)**      |                      |                      |                        |                     |
| mean ± SD                       | 23.8 ± 3.4           | 24.3 ± 3.4           | 22.9 ± 3.3             | < 0.01              |
| > 24                            | 659 (46.1)           | 501 (76.0)           | 158 (24.0)             | < 0.01              |
| ≤ 24                            | 772 (54.0)           | 434 (56.2)           | 338 (43.8)             |                     |
| **Smoke**                       |                      |                      |                        | < 0.01              |
| No                              | 822 (57.4)           | 346 (42.1)           | 476 (57.9)             |                     |
| Yes                             | 609 (42.6)           | 589 (96.7)           | 20 (3.3)               |                     |
| **Drink**                       |                      |                      |                        | < 0.01              |
| No                              | 821 (57.4)           | 354 (43.1)           | 467 (56.9)             |                     |
| Yes                             | 610 (42.6)           | 581 (95.3)           | 29 (4.8)               |                     |
| **Tumor site**                  |                      |                      |                        | < 0.01              |
| Upper                           | 334 (23.3)           | 271 (81.1)           | 63 (18.9)              |                     |
| Middle                          | 345 (24.1)           | 205 (59.4)           | 140 (40.6)             |                     |
| Lower                           | 662 (46.3)           | 416 (62.8)           | 246 (37.2)             |                     |
| Others                          | 90 (6.3)             | 43 (47.8)            | 47 (52.2)              |                     |
| **Histology differentiation**   |                      |                      |                        | 0.23                |
| Well-/moderately differentiated | 29 (2.1)             | 22 (75.9)            | 7 (24.1)               |                     |
| Poorly/undifferentiated         | 1326 (97.9)          | 864 (65.2)           | 462 (34.8)             |                     |
| **Signet-ring cell proportion (%)** |                   |                      |                        | 0.02                |
| ≤ 10                            | 155 (10.8)           | 117 (75.5)           | 38 (24.5)              |                     |
| > 10, ≤ 50                      | 954 (66.7)           | 616 (64.6)           | 338 (35.4)             |                     |
| > 50, ≤ 90                      | 235 (16.4)           | 143 (60.9)           | 92 (39.2)              |                     |
| > 90                            | 87 (6.1)             | 59 (67.8)            | 28 (32.2)              |                     |
| **Lauren type**                 |                      |                      |                        | < 0.01              |
| Intestinal                      | 73 (5.1)             | 61 (83.6)            | 12 (16.4)              |                     |
| Diffused                        | 910 (63.6)           | 557 (61.2)           | 353 (38.8)             |                     |
| Mixed                           | 353 (24.7)           | 261 (73.9)           | 92 (26.1)              |                     |
| Unknown                         | 95 (6.6)             | 56 (59.0)            | 39 (41.0)              |                     |
| **T stage**                     |                      |                      |                        | 0.02                |
| T1                              | 411 (28.7)           | 246 (59.9)           | 165 (40.2)             |                     |
| T2                              | 172 (12.0)           | 119 (69.2)           | 53 (30.8)              |                     |
| T3                              | 322 (22.5)           | 227 (70.5)           | 95 (29.5)              |                     |
| T4                              | 526 (36.8)           | 343 (65.3)           | 183 (34.8)             |                     |
| **N stage**                     |                      |                      |                        | 0.54                |
| N0                              | 573 (40.0)           | 365 (63.7)           | 208 (36.3)             |                     |
| N1                              | 192 (13.4)           | 130 (67.7)           | 62 (32.3)              |                     |
|                      | N2   | N3   | Metastasis |
|----------------------|------|------|------------|
|                      | 219  | 150  | 69         |
|                      | (15.3)| (68.5)| (31.5)     |
| Metastasis           |      |      | < 0.01     |
| No                   | 1348 | 892  | 456        |
|                      | (94.2)| (66.2)| (33.8)     |
| Yes                  | 83   | 43   | 40         |
|                      | (5.8 )| (51.8)| (48.2)     |
| Adjuvant chemotherapy|      |      | 0.51       |
| No                   | 924  | 598  | 326        |
|                      | (64.6)| (64.7)| (35.3)     |
| Yes                  | 507  | 337  | 170        |
|                      | (35.4)| (66.5)| (33.5)     |
| Neoadjuvant chemotherapy| |      | 0.72      |
| No                   | 1315 | 861  | 454        |
|                      | (91.9)| (65.5)| (34.5)     |
| Yes                  | 116  | 74   | 42         |
|                      | (8.1)| (63.8)| (36.2)     |
| Nerve invasion       |      |      | 0.02       |
| No                   | 313  | 184  | 129        |
|                      | (21.9)| (58.8)| (41.2)     |
| Yes                  | 714  | 477  | 237        |
|                      | (49.9)| (66.8)| (33.2)     |
| Unknown              | 404  | 274  | 130        |
|                      | (28.2)| (67.8)| (32.2)     |
| Lymphovascular invasion| |      | 0.02      |
| No                   | 416  | 249  | 167        |
|                      | (29.1)| (59.9)| (40.1)     |
| Yes                  | 554  | 373  | 181        |
|                      | (38.7)| (67.3)| (32.7)     |
| Unknown              | 461  | 313  | 148        |
|                      | (32.2)| (67.9)| (32.1)     |
| HER-2                |      |      | 0.28       |
| Negative             | 1082 | 702  | 380        |
|                      | (85.3)| (64.9)| (35.1)     |
| Positive             | 187  | 129  | 58         |
|                      | (14.7)| (69.0)| (31.0)     |
| Lymph nodes removed  |      |      | < 0.01     |
| ≤ 16                 | 171  | 131  | 40         |
|                      | (12.0)| (76.6)| (23.4)     |
| > 16, ≤ 30           | 585  | 395  | 190        |
|                      | (40.9)| (67.5)| (32.5)     |
| > 30                 | 675  | 409  | 266        |
|                      | (47.2)| (60.6)| (39.7)     |

1The P values for age and BMI (continuous variables) were calculated from Wilcoxon–Mann–Whitney test; The P value for other categorical variables were calculated from χ² test.

2Tumor site was divided by upper (cardia, fundus, gastroesophageal junction), middle (body, lesser/greater curvature), lower (antrum, pylorus) and other (gastric remnant, anastomosis, linitis plastica) parts of the stomach.

P < 0.05 indicates statistical significance. Row percentage was reported for the overall sample. BMI: Body mass index; HER-2: Human epidermal growth factor receptor 2.

**Comparison of overall survival in GSRC between the sexes**

The survival curves in Figure 1 depict the survival probability based on the sex difference. Menstrual female patients had a significantly better overall survival than the male and menopausal female groups (P < 0.01). Survival analysis showed better prognosis of menstrual female patients in the non-adjuvant chemotherapy group (P < 0.01) and the inadequate survival advantages of menstrual female patients in the adjuvant chemotherapy group (P = 0.73) (Figure 2). We compared overall survival between the sexes with different levels of signet-ring cells (Figure 3). Menstrual female patients had a survival advantage compared with male and menopausal female groups; however, this advantage was not significant in the GSRC group with > 50% signet-ring cells (Supplementary Figure 1).
Table 2 Multivariate analysis for mortality risk in gastric cancer patients with signet ring cells

| Variable                                      | HR (95%CI)       | P value |
|-----------------------------------------------|------------------|---------|
| Sex disparity                                 |                  |         |
| Male                                          | Ref              |         |
| Menstrual female                              | 0.58 (0.42–0.82) | < 0.01  |
| Menopausal female                             | 0.91 (0.72–1.14) | 0.42    |
| BMI (kg/m²)                                   |                  |         |
| > 24                                          | Ref              |         |
| ≤ 24                                          | 1.24 (1.02–1.51) | 0.03    |
| Signet-ring cell proportion (%)               |                  |         |
| ≤ 10                                          | Ref              |         |
| > 10, ≤ 50                                    | 0.97 (0.72–1.32) | 0.86    |
| > 50, ≤ 90                                    | 0.79 (0.53–1.17) | 0.25    |
| > 90                                          | 1.03 (0.63–1.70) | 0.90    |
| T stage                                       |                  |         |
| T1                                            | Ref              |         |
| T2                                            | 1.58 (0.87–2.88) | 0.13    |
| T3                                            | 4.20 (2.57–6.84) | < 0.01  |
| T4                                            | 5.96 (3.67–9.69) | < 0.01  |
| N stage                                       |                  |         |
| N0                                            | Ref              |         |
| N1                                            | 1.30 (0.87–1.93) | 0.195   |
| N2                                            | 1.92 (1.34–2.75) | < 0.01  |
| N3                                            | 3.29 (2.38–4.55) | < 0.01  |
| Adjuvant chemotherapy                         |                  |         |
| No                                            | Ref              |         |
| Yes                                           | 0.75 (0.62–0.91) | < 0.01  |
| Neoadjuvant chemotherapy                      |                  |         |
| No                                            | Ref              |         |
| Yes                                           | 2.34 (1.79–3.04) | < 0.01  |
| Nerve invasion                                |                  |         |
| No                                            | Ref              |         |
| Yes                                           | 1.50 (0.93–2.43) | 0.10    |
| Unknown                                       | 1.47 (0.88–2.46) | 0.14    |
| Lymphovascular invasion                       |                  |         |
| No                                            | Ref              |         |
| Yes                                           | 1.39 (1.02–1.90) | 0.04    |
| Unknown                                       | 1.26 (0.89–1.80) | 0.19    |

The Cox model included gender, BMI, signet-ring cell proportion, T stage, N stage, adjuvant chemotherapy, neoadjuvant chemotherapy, nerve invasion, and lymphovascular invasion. P < 0.05 indicates statistical significance. BMI: Body mass index.
Table 3 Associations of sex and risk of mortality among gastric cancer patients with signet-ring cells by subgroups

| Variable                        | Male          | Menstrual female | Menopausal female | P-interaction |
|---------------------------------|---------------|------------------|-------------------|---------------|
|                                 | \( n (\%) \) | \( HR (95\%CI) \) | \( n (\%) \) | \( HR (95\%CI) \) | \( n (\%) \) | \( HR (95\%CI) \) |             |
| **BMI (kg/m\(^2\))**           |               |                  |                   |               |
| > 24                            | 501 (53.6)    | Ref              | 41 (22.7)         | 0.56 (0.27–1.16) |
| ≤ 24                            | 434 (46.4)    | Ref              | 140 (77.4)        | 0.58 (0.39–0.85) |
| **Signet-ring cell proportion (%)** |               |                  |                   |               |
| ≤ 50                            | 733 (78.4)    | Ref              | 129 (71.3)        | 0.56 (0.38–0.82) |
| > 50                            | 202 (21.6)    | Ref              | 52 (28.7)         | 0.73 (0.33–1.61) |
| **Adjuvant chemotherapy**       |               |                  |                   | < 0.001       |
| No                              | 598 (64.0)    | Ref              | 119 (65.8)        | 0.38 (0.22–0.65) |
| Yes                             | 337 (36.0)    | Ref              | 62 (34.3)         | 0.83 (0.53–1.29) |
| **Neoadjuvant chemotherapy**    |               |                  |                   | < 0.001       |
| No                              | 861 (92.1)    | Ref              | 165 (91.2)        | 0.53 (0.36–0.77) |
| Yes                             | 74 (7.9)      | Ref              | 16 (8.8)          | 0.97 (0.76–1.25) |
| **Nerve invasion**              |               |                  |                   | < 0.029\(^4\) |
| No                              | 184 (19.7)    | Ref              | 54 (29.8)         | 0.36 (0.07–1.86) |
| Yes                             | 477 (51.0)    | Ref              | 87 (48.1)         | 0.60 (0.40–0.89) |
| Unknown                         | 274 (29.3)    | Ref              | 40 (22.1)         | 0.63 (0.31–1.39) |
| **Lymphovascular invasion**     |               |                  |                   | < 0.001\(^4\) |
| No                              | 249 (26.6)    | Ref              | 70 (38.7)         | 0.89 (0.40–1.95) |
| Yes                             | 373 (39.9)    | Ref              | 56 (30.9)         | 0.49 (0.30–0.80) |
| Unknown                         | 313 (33.5)    | Ref              | 55 (30.4)         | 0.68 (0.37–1.23) |

1 Column percentage was reported for the overall sample; percentage can differ slightly from 100% because of rounding.
2 The Cox proportional hazards model included gender, BMI, signet-ring cell proportion, T stage, N stage, adjuvant chemotherapy, neoadjuvant chemotherapy, nerve invasion, and lymphovascular invasion.
3 Wald test was used to examine the interaction term between sex (male, menstrual female, and menopausal female) and BMI, signet-ring cell proportion, adjuvant chemotherapy, neoadjuvant chemotherapy, nerve invasion, and lymphovascular invasion.
4 The \( P \) value shows the outcome of interaction test between sex difference and nerve invasion (no vs yes) and lymphovascular invasion (no vs yes).

BMI: Body mass index. \( P < 0.05 \) indicates statistical significance.

DISCUSSION

Although the incidence of GC has been decreasing, this disease remains the third cause of cancer mortality worldwide and in China. The proportion of GSRC in all GC cases has been increasing recently, especially in the young and female populations. There are obvious differences on morbidity of GSRC between the sexes. To find a new treatment and improve the overall survival of GSRC, this study has clinical significance to investigate the disparities of reproductive factors between male and female GSRC patients.

In this study, we focused on the influence of the sex-specific differences on the prognosis of GSRC. Our results showed that there was a stronger positive association with overall survival in menstrual female patients with GSRC, compared to that of the male or menopause female patients. The findings of the present large patient-based retrospective study may provide valuable insights into pathways for reducing GSRC mortality in the future.

The multivariate analysis results in our study showed that being a menstrual woman was a protective factor (HR = 0.58, 95%CI: 0.42–0.82) against GSRC. A similar effect was previously reported in various types of GCs\([17,18]\). In a study with 758 patients, Kim et al\([7]\) proposed that female reproductive hormones might be a potentially protective factor against intestinal-type GC, and the incidence of intestinal-type GC after the menopause increased and became comparable to that in men. A Japanese study revealed that the risk of GC was lower in menstrual women (HR = 0.33, 95%CI: 0.23–0.49). Protective effects were observed in differentiated histological types (HR = 0.25, 95%CI: 0.11–0.55) and undifferentiated histological types (HR = 0.39, 95%CI: 0.23–0.63)\([19]\). The aforementioned consistent
results demonstrate the effects of female reproductive factors in reducing the risks of different GCs. In a large Chinese prospective study with female subjects, the risks of GC increased with age of menopausal women (HR = 0.80 per 5-year increase in the menopausal age, 95%CI: 0.66–0.97) [20]. A similar finding was also obtained in a cohort study including 1 million women whose risks of GC in the menopausal age were considerably higher than those in the menstrual age (RR = 1.46, 95%CI: 1.07–2.0 and RR = 1.59, 95%CI: 1.15–2.20, respectively) from the United Kingdom [21]. Our results indicate that the effect of female reproductive factors on GSRC development is steady and robust.

Here, we hypothesize that sex hormones or their receptors, such as estrogen and estrogen receptor (ER), are the key inducers of the protective effects of female reproductive factors against GSRC. The influence of estrogen has been studied by other researchers, but the results were controversial [22]. Estrogens regulate the tissue growth, differentiation, and function, which is mediated by ER-α and ER-β. The oncological importance of estrogen and ER in carcinomas occurring in the breast and ovaries has been investigated but not in GCs. The expression of ER in the stomach is a basis on which to explore the relationship between sex hormones and survival of GC. Some researchers have demonstrated the expression of ER in gastric tissues, which provides a basis for the probable functions of estrogen in this respect [23–25]. Hess et al [26] established that ERs and female sex hormones were expressed in the male reproductive tract and may have some functions. The protective effect of estrogen was discovered also in men who received hormonal therapy for prostate cancer; notably, the results showed a decrease risk of GC [27].

ER has several types, including ERα, ERβ and ERγ. The biological actions of estrogen are mediated through two specific ERs, ERα and ERβ, which belong to the nuclear receptor superfamily [28]. Zhao et al [25] and Matsuyama et al [29] reported that both ERα, ERβ were expressed in poorly differentiated adenocarcinoma specifically in gastric signet-ring cell adenocarcinomas with characteristics of sex hormone dependency. Different effects of these two ER types were found in various studies. For example, Kameda et al [27] proposed that ERα expressed in diffuse-type GC promoted the proliferation of ERα-positive GC cells. The suggested mechanism was that the activation of the ERα pathway stimulated cancer cell proliferation by activating the hedgehog pathway in a ligand-dependent but dose-independent manner via Shh induction of diffuse-type GC. ERβ is homologous to ERα, particularly in the DNA-binding domain, but it is structurally and functionally different. ERβ manifested strong cytoplasmic staining with anti-ERβ antibody in addition to the stained nuclei [29]. This result provides evidence for the potential of GSRC treatment targets. Recently, using genomic analysis, Kang et al [29] identified ERγ as a potential tumor suppressor in GC. The molecular mechanisms of its action suggest that the activation of ERγ by the antagonizing Wnt signaling through DY131 could suppress GC cell growth and tumorigenesis. Studies on tumorigenesis regulated by estrogens or estrogen receptors are rare but will be urgently needed in the future.

Since chemoresistance is a distinct feature of GSRC, we noticed that the adjuvant chemotherapy was a protective factor in multivariate analysis. Then, we performed further subgroup analysis on adjuvant chemotherapy effects. Interestingly, protective effects exerted by female reproductive factors were observed only in the nonadjuvant chemotherapy group (HR = 0.38, 95%CI: 0.22–0.56) and the non-neoadjuvant chemotherapy group (HR = 0.53, 95%CI: 0.36–0.77). However, female reproductive factors lost their advantages and did not improve the survival after chemotherapy. It is possible that these conditions of poor survival and chemoresistance are mediated by female reproductive factors, such as ERα and ERβ, with unknown mechanism. Recently, Wang et al [30] proposed that the loss of ERβ in
GSRC cells might increase the potential for malignant invasion into the deep tissues easier through the mTOR signaling pathway. Therefore, ERβ might inhibit the malignancy of GSRC and can thus become a potential target in its adjuvant treatment. The investigation of Wang did not discuss the connection between ERβ and chemotherapy. We noticed that the prognostic trends are similar in all three studied groups. However, in the subgroup analysis of adjuvant chemotherapy, the mean survival time in the menstrual female group (41.4 mo) was the shortest compared to those of the male (47.6 mo) and menopausal female (45.1 mo) groups. We considered that the probable reason was the proportion of signet-ring cells in GCs. However, no association was identified between the signet-ring cell proportion and influence of female reproductive factors on the prognosis of subjects who received chemotherapy. The results of recent studies confirm the difficulties to understand the possible mechanism between sex hormones and chemoresistance in GSRC. However, more research on this topic needs to be undertaken to clearly elucidate the association between ER and chemotherapy outcomes.

We investigated the effects of female reproductive factors on the prognosis of the GSRC with various proportions of signet-ring cells. Being a menstrual female was a protective factor (HR = 0.56, 95%CI: 0.38–0.82) and was associated with better overall survival than that of menopausal women and men with GSRC cells < 50%. However, menstrual women lost their GSRC-associated advantages over menopausal women at a proportion of the signet-ring cells > 50%. We supposed that ERβ downregulation or ectopic expression in the cytoplasm could lead to a worse prognosis of GSRC with a higher proportion of signet-ring cells. Nevertheless, the probable mechanism remains unclear. Future studies on the topic are therefore highly recommended.

This is the first large population study focused on the relationship between female reproductive factors and GSRC with an 8-year follow-up. Our results highlight the significant effect of female reproductive factors on GSRC prognosis. The clinical importance of our present findings is critical as they have outlined the prognostic role of female reproductive factors in GSRC. Therefore, further strong evidence is provided which will increase the GSRC treatment effectiveness. In this study, we have also
investigated the effect of female reproductive factors on survival in a multidimensional aspect with robust statistics such as multivariable Cox proportional hazards model and different subgroups, which could considerably diminish the impact of confounders and explore the potential effect in a specific group.

Despite the aforementioned strengths of our study, several limitations have to be acknowledged. First, the data concerning the expression levels of ER and progesterone receptor (PR) were unavailable. Thus, we cannot conduct further analysis on the effects of ER and PR on GSRC prognosis and other molecular mechanisms. Further investigations are needed to clarify the biological role of estrogen or ER in the carcinogenesis and chemoresistance of GSRC. Second, future studies with a more specific measure of signet-ring cells in GC and more comprehensive long-term outcomes (e.g., the recurrence or chemoresistance, could offer more information) will be needed to verify the conclusion in this study.

CONCLUSION

Sex differences, especially female reproductive factors, might be protective against GSRC and serve as a significant prognostic factor. Further studies including more comprehensive measures will be essential to elucidate the mechanism of action of female reproductive factors on GSRC.
ARTICLE HIGHLIGHTS

Research background
Gastric signet-ring cell carcinoma (GSRC) is a distinct type of gastric cancer (GC), and its incidence has been steadily increasing. GSRC in early and advanced stages is more frequently observed in younger female patients than in gastric adenocarcinomas.

Research motivation
The effect of female reproductive factors on GSRC tumorigenesis and tumor development remains unclear.

Research objectives
The purpose of this study was to estimate the effects of female reproductive factors on the prognosis of GSRC.

Research methods
Our study involved 1431 participants who were histologically confirmed with GC with signet-ring cells and underwent curative resections between January 2011 and December 2018 at the Cancer Hospital, Chinese Academy of Medical Sciences, China. Cox multivariable model was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between sex factors and survival of GC patients with signet-ring cell carcinoma. Subgroup analyses were conducted by: (1) Body mass index; (2) Signet-ring cell proportion; (3) Adjuvant chemotherapy; (4) Neoadjuvant chemotherapy; (5) Nerve invasion; and (6) Lymphatic vessel invasion to explore if the impact of the sex difference was stronger in certain groups.

Research results
The menstrual female subjects had a significantly lower risk of mortality (HR = 0.58, 95%CI: 0.42–0.82) than male participants in the multivariable model. The effect appeared to be more substantial among certain subgroup analyses.

Research conclusions
There was a stronger positive association with overall survival in menstrual female patients with GSRC, compared to in male or menopause female patients.

Research perspectives
Future studies with a more specific measure of signet-ring cells in GC and more comprehensive long-term outcomes (e.g., the recurrence or chemoresistance, could offer more information) will be needed to verify the conclusion in this study.

FOOTNOTES

Author contributions: All of the authors contributed to this work; Li Y and Tian YT designed the research study and performed the research; Li Y collected the data, performed the statistical analysis, and drafted the manuscript; Li Y, Zhong YX, Xu Q, and Tian YT participated in discussion and manuscript revision; All authors have read and approve the final version of the manuscript and agreed to be accountable for all aspects of the work.

Supported by National Natural Science Foundation of China, No. 82072734.

Institutional review board statement: Ethical approval was obtained through the Chinese Academy of Medical Science (Beijing, China).

Informed consent statement: All participants gave written informed consent.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Data sharing statement: All data included in this study are available on reasonable request from the corresponding author.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *Cancer J Clin* 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/cacac.21492]

2. Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X, He J. Cancer incidence and mortality in China, 2013. *Cancer Lett* 2017; 401: 63-71 [PMID: 28476483 DOI: 10.1016/j.canlet.2017.04.024]

3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. *Cancer J Clin* 2016; 66: 115-132 [PMID: 26808342 DOI: 10.3322/cacac.21338]

4. Chandanas E, Lagergren J. Oestrogen and the enigmatic male predominance of gastric cancer. *Eur J Cancer* 2008; 44: 2397-2403 [PMID: 18755853 DOI: 10.1016/j.ejca.2008.07.031]

5. Freedman ND, Derakhshian MH, Abnet CC, Schatzkin A, Hollenbeck AR, McColl KE. Male predominance of upper gastrointestinal adenocarcinoma cannot be explained by differences in tobacco smoking in men versus women. *Eur J Cancer* 2010; 46: 2473-2478 [PMID: 20605442 DOI: 10.1016/j.ejca.2010.05.005]

6. Ibrahim A, Morais S, Ferro A, Lunet N, Pelleito B. Sex-differences in the prevalence of Helicobacter pylori infection in pediatric and adult populations: Systematic review and meta-analysis of 244 studies. *Dig Liver Dis* 2017; 49: 742-749 [PMID: 28495503 DOI: 10.1016/j.dld.2017.03.019]

7. Kim SM, Min BH, Lee J, An JY, Lee JH, Sohn TS, Bae JM, Kim JJ, Kang WK, Kim S, Choi MG. Protective Effects of Female Reproductive Factors on Lauren Intestinal-Type Gastric Adenocarcinoma. *Yonsei Med J* 2018; 59: 28-34 [PMID: 29214773 DOI: 10.3349/ymj.2018.59.1.28]

8. Zhang QQ, Chen JL, Luo Y, Mathur MB, Anagnostis P, Nurmatov U, Talibov M, Zhang J, Hawrylowicz CM, Lumsden MA, Critchley H, Sheikhi A, Lundbäck B, Lässer C, Kankaanranta H, Lee SH, Nwaru BI. Menopausal hormone therapy and women’s health: An umbrella review. *PloS Med* 2021; 18: e1003731 [PMID: 34339416 DOI: 10.1371/journal.pmed.1003731]

9. Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. *World J Gastroenterol* 2015; 21: 11428-11438 [PMID: 26521307 DOI: 10.3748/wjg.v21.i40.11428]

10. Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse And So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. *Acta Pathol Microbiol Scand* 1965; 64: 31-49 [PMID: 14320675]

11. Nagtegaal ID, Ozde RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA; WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. *Histopathology* 2020; 76: 182-188 [PMID: 31433515 DOI: 10.1111/his.13975]

12. Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. *Gan 1968; 59*: 251-258 [PMID: 5726267]

13. Arai T. Where does signet-ring cell carcinoma come from and where does it go? *Gastric Cancer* 2019; 22: 651-652 [PMID: 30963318 DOI: 10.1007/s10120-019-00960-w]

14. Kao YC, Fang WL, Wang RF, Li AF, Yang MH, Wu CW, Shyr YM, Huang KH. Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer. *Gastric Cancer* 2019; 22: 255-263 [PMID: 30069742 DOI: 10.1007/s10120-018-0860-8]

15. Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Gregg RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Kessler RI, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poutsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2016; 14: 1286-1312 [PMID: 27697982]

16. Chen C, Lu FC, Department of Disease Control Ministry of Health, PR China. The guidelines for prevention and control of overweight and obesity in Chinese children. *Biomed Environ Sci* 2004; 17 Suppl. 1-36 [PMID: 15807473]

17. Kaneko S, Tamakoshi A, Ohto Y, Mizoue T, Yoshimura T; JACC Study Group. Menstrual and reproductive factors and the mortality risk of gastric cancer in Japanese menopausal females. *Cancer Causes Control* 2003; 14: 53-59 [PMID: 12708725 DOI: 10.1023/a:1022596104796]

18. Friso S, Kreiger N, Gallinger S, Tomlinson G, Cotterchio M. Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the anadian national enhanced cancer surveillance system. *Ann Epidemiol* 2006; 16: 908-916 [PMID: 16843679 DOI: 10.1016/j.annepidem.2006.03.001]

19. Persson C, Inoue M, Sasazuki S, Kurahashi N, Iwasaki M, Ye W, Tsugane S; JPHC Study Group. Female reproductive factors and the risk of gastric cancer in a large-scale population-based cohort study in Japan (JPHC study). *Eur J Cancer Prev* 2008; 17: 345-353 [PMID: 18562960 DOI: 10.1097/CEJ.0b013e3282f521e4]

20. Freedman ND, Chow WH, Gao YT, Shu XO, Ji BT, Yang G, Lubin JH, Li HL, Rothman N, Zheng W, Abnet CC.
Menstrual and reproductive factors and gastric cancer risk in a large prospective study of women. *Gut* 2007; 56: 1671-1677 [PMID: 17627962 DOI: 10.1136/gut.2007.129411]

21 Green J, Roddam A, Pirie K, Kirichek O, Reeves G, Beral V; Million Women Study collaborators. Reproductive factors and risk of oesophageal and gastric cancer in the Million Women Study cohort. *Br J Cancer* 2012; 106: 210-216 [PMID: 22127287 DOI: 10.1038/bjc.2011.525]

22 Brusselaers N, Maret-Ouda J, Konings P, El-Serag HB, Lagergren J. Menopausal hormone therapy and the risk of oesophageal and gastric cancer. *Int J Cancer* 2017; 140: 1693-1699 [PMID: 28006838 DOI: 10.1002/ijc.30588]

23 Zhang Y, Wang Y, Wan Z, Liu S, Cao Y, Zeng Z. Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. *PloS One* 2014; 9: e90362 [PMID: 24587339 DOI: 10.1371/journal.pone.0090362]

24 Wang M, Pan JY, Song GR, Chen HB, An JJ, Ou SQ. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothrombin alpha and clinicopathological parameters. *Eur J Surg Oncol* 2007; 33: 195-201 [PMID: 17046193 DOI: 10.1016/j.ejso.2006.09.009]

25 Zhao HX, Gu SZ, Liu SX, Pan BR. Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues. *World J Gastroenterol* 2003; 9: 665-669 [PMID: 12679906 DOI: 10.3748/wjg.v9.i4.665]

26 Hess RA, Cooke PS. Estrogen in the male: a historical perspective. *Biol Reprod* 2018; 99: 27-44 [PMID: 29438493 DOI: 10.1093/biolre/ioy043]

27 Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M, Onishi H, Katano M. Oestrogen receptor-alpha contributes to the regulation of the hedgehog signalling pathway in Eralpha-positive gastric cancer. *Br J Cancer* 2010; 102: 738-747 [PMID: 20087349 DOI: 10.1038/sj.bjc.6605517]

28 Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, Nakachi K, Gustafsson JA, Hayashi S. Estrogen receptor beta is expressed in human stomach adenocarcinoma. *J Cancer Res Clin Oncol* 2002; 128: 319-324 [PMID: 12073050 DOI: 10.1007/s00432-002-0336-3]

29 Kang MH, Choi H, Oshima M, Cheong JH, Kim S, Lee JH, Park YS, Choi HS, Kweon MN, Park CG, Lee JS, Mills GB, Myung SJ, Park YY. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. *Nat Commun* 2018; 9: 1920 [PMID: 29765046 DOI: 10.1038/s41467-018-04244-2]

30 Wang X, Xia X, Xu E, Yang Z, Shen X, Du S, Chen X, Lu X, Jin W, Guan W. Estrogen Receptor Beta Prevents Signet Ring Cell Gastric Carcinoma Progression in Young Patients by Inhibiting Pseudopodia Formation via the mTOR-Argc1b/EVL Signaling Pathway. *Front Cell Dev Biol* 2020; 8: 592919 [PMID: 33553141 DOI: 10.3389/fcell.2020.592919]
